- Home
- VBTX vs JANX Comparison
VBTX vs JANX Comparison
Compare VBTX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBTX
- JANX
- Stock Information
- Founded
- VBTX 2009
- JANX 2017
- Country
- VBTX United States
- JANX United States
- Employees
- VBTX N/A
- JANX N/A
- Industry
- VBTX Major Banks
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- VBTX Finance
- JANX Health Care
- Exchange
- VBTX Nasdaq
- JANX Nasdaq
- Market Cap
- VBTX 1.7B
- JANX 1.5B
- IPO Year
- VBTX 2014
- JANX 2021
- Fundamental
- Price
- VBTX $34.34
- JANX $22.95
- Analyst Decision
- VBTX Buy
- JANX Strong Buy
- Analyst Count
- VBTX 6
- JANX 8
- Target Price
- VBTX $33.00
- JANX $86.63
- AVG Volume (30 Days)
- VBTX 701.3K
- JANX 838.5K
- Earning Date
- VBTX 10-21-2025
- JANX 08-07-2025
- Dividend Yield
- VBTX 2.56%
- JANX N/A
- EPS Growth
- VBTX 31.14
- JANX N/A
- EPS
- VBTX 2.10
- JANX N/A
- Revenue
- VBTX $424,480,000.00
- JANX $439,000.00
- Revenue This Year
- VBTX $12.36
- JANX N/A
- Revenue Next Year
- VBTX $4.80
- JANX $591.60
- P/E Ratio
- VBTX $16.35
- JANX N/A
- Revenue Growth
- VBTX 16.89
- JANX N/A
- 52 Week Low
- VBTX $20.37
- JANX $21.97
- 52 Week High
- VBTX $34.46
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- VBTX 70.61
- JANX 44.86
- Support Level
- VBTX $31.83
- JANX $22.90
- Resistance Level
- VBTX $34.43
- JANX $24.00
- Average True Range (ATR)
- VBTX 0.58
- JANX 1.12
- MACD
- VBTX 0.13
- JANX -0.09
- Stochastic Oscillator
- VBTX 96.48
- JANX 37.48
About VBTX Veritex Holdings Inc.
Veritex Holdings Inc is engaged in the provision of commercial banking products and services to small to medium-sized businesses and professionals. The bank provides a range of banking services to individual and corporate customers, which include commercial and retail lending, and the acceptance of checking and savings deposits. It offers a suite of online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, as well as automated teller machines, and banking by telephone, mail and personal appointment. The company's primary sources of revenue are derived from interest and dividends earned on loans, debt and equity securities and other financial instruments.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.